Posts tagged Non–small-cell lung cancer (NSCLC)
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib

Crizotinib is active as second-line therapy against MET-mediated resistance to alectinib in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer and can be used in combination.

Repeat molecular analyses including assessment of MET amplification can help guide therapy in ALK-positive non–small-cell lung cancer. READ ARTICLE

Clinical Lung Cancer DOI:10.1016/j.cllc.2021.04.008

Authors: Jingran Ji, Anupam Mitra, D. Ross Camidge, Jonathan W. Riess

Read More
Case StudyKirk SmithALK inhibitor resistance, ALK mutation, Non–small-cell lung cancer (NSCLC), MET inhibition, MET amplification, rechallenge
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

Currently, the role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as adjuvant therapy for early-stage non–small-cell lung cancer after complete surgical tumor resection remains under investigation. We present the rationale and study design for the ADAURA (ClinicalTrials.gov identifier, NCT02511106) trial, a multicenter, double-blind, randomized, placebo-controlled study. READ ARTICLE

Clinical Lung Cancer DOI:10.1016/j.cllc.2018.04.004

Authors: Yi-LongWu, Roy S. Herbst, Helen Mann, Yuri Rukazenkov, Marcelo Marotti and MasahiroTsuboi

Read More
Clinical TrialsKirk SmithAdjuvant therapy, EGFR-TKI, Non–small-cell lung cancer (NSCLC), Surgery, tyrosine kinase inhibitor (TKI)